

FASKEN

Fasken Martineau DuMoulin LLP
Barristers and Solicitors
Patent and Trade-mark Agents

333 Bay Street, Suite 2400
P.O. Box 20
Toronto, Ontario M5H 2T6
Canada

T +1 416 366 8381
+1 800 268 8424
F +1 416 364 7813
fasken.com

March 21, 2022
File No.: 264476.00050

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Dear Sirs/Mesdames:

**Re: GeneTether Therapeutics Corporation (the “Company”)
Final Long Form Prospectus**

We refer to the final long form prospectus dated March 21, 2022 of the Company in relation to the offering of units comprised of one common share and one common share purchase warrant of the Company (the “**Prospectus**”).

We hereby consent to the reference to our firm name in the introduction and under the headings “Agency Agreement” and “Experts” and to the reference to our firm name and to the use of our opinions under the headings “Eligibility for Investment” and “Certain Canadian Federal Income Tax Considerations” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that is derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

This letter is delivered to the addressees pursuant to the requirements of Section 9.2(a)(viii) of National Instrument 41-101.

Yours truly,

“FASKEN MARTINEAU DuMOULIN LLP”

